Corneal Cross-Linking (CXL)

Corneal Collagen Cross-Linking with riboflavin (CXL or sometimes also abbreviated as C3R) is a non-invasive treatment shown to slow or halt the progression of keratoconus. Undergoing Corneal Collagen Cross-Linking in the early stages may help preserve vision and halt the progress of keratoconus. While the treatment will not correct vision or eliminate the need for glasses and/or contact lenses, it can help maintain the current level of vision and is meant to prevent vision from worsening. It can also facilitate the use of contact lenses. How Corneal Collagen Cross-Linking Works Corneal Collagen Cross-Linking increases the collagen bonds in the cornea that have been weakened by keratoconus. The treatment induces the natural anchors within the corneal fibers to prevent bulging. Its goal is to increase the strength of the corneal tissue. It may help to prevent further deterioration of vision by stabilizing and strengthening the cornea. Corneal Collagen Cross-Linking can greatly reduce the need for a corneal transplant in the future. Benefits of Corneal Collagen Cross-Linking Greater corneal rigidity Increased corneal resistance and biomechanical stability Prevent disease progression May defer the need for a corneal transplant procedure May reduce the nearsightedness and astigmatism associated with keratoconus Enhance contact lens wear Reduced risk of ectasia